Antiplatelet strategies
University of Rome ‘Sapienza’ Rome, Italy
* Correspondence: Carlo Patrono, Seconda Facoltà di Medicina e Chirurgia, Ospedale Sant'Andrea, Via di Grottarossa 1035, 00189 Roma, Italy.
Abstract
Antiplatelet therapy has now been shown to reduce the risk of serious vascular events by about one-quarter, not just among patients with acute coronary syndromes, stroke or TIA, but also among other categories of patients with coronary or peripheral arterial disease or those at high risk of embolism. Antiplatelet strategies based on permanent modifications of a platelet protein by a short-lived active moiety (e.g., aspirin or clopidogrel) are ideally suited to this effect. The available evidence supports daily doses of aspirin in the range 75–100 mg for the long-term prevention of serious vascular events in high-risk patients, as the best strategy to maximize both efficacy and safety. Other antiplatelet drugs can be substituted for or combined with aspirin in some conditions.
Key Words: Aspirin • clopidogrel • cyclooxygenase inhibitors • GPIIb/11Ia blockers • TP antagonists
Footnotes
Supported by a grant from the Italian Ministry of University and Research to the Center of Excellence on Aging of the University of Chietie ‘G. D'Annunzio’.
References
- Kroll MH, Sullivan R. Mechanisms of platelet activation. Loscalzo J, Schafer AI. Thrombosis and Hemorrhage. Baltimore: William & Wilkins; 1998. p. 261–291
- Patrono C. Pharmacology of antiplatelet agents. Loscalzo J, Schafer AI. Thrombosis and Hemorrhage. Baltimore: William & Wilkins; 1998. p. 1181–1192
- Kaushansky K. Regulation of megakaryopoiesis. Loscalzo J, Schafer AI. Thrombosis and Hemorrhage. Baltimore: William & Wilkins; 1998. p. 173–193
- Fitzpatrick FA, Sorberman R. Regulated formation of eicosanoids. J Clin Invest. 2001;107:1347–1351[Web of Science][Medline]
- Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1ß synthesis. J Cell Biol. 2001;154:485–490
[Abstract/Free Full Text] - Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenaseselective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7–13[CrossRef][Web of Science][Medline]
- Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287–1294
[Free Full Text] - Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. J Biol Chem. 1996;271:33157–33160
[Free Full Text] - Cipollone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 1997;96:1109–1116
[Abstract/Free Full Text] - Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S–63S (suppl)
[Free Full Text] - Antithrombotic Trialists' Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in highrisk patients. BMJ. 2001;: in press
- Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and highdose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet. 1999;355:1295–1305
- Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–1372
- García Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39
[Abstract/Free Full Text] - Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891–896[Web of Science][Medline]
- Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202–207[CrossRef][Medline]
- CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339[CrossRef][Web of Science][Medline]
- CURE Steering Committee. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med. 2001;345:494–502
[Abstract/Free Full Text] - Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201–206
[Abstract/Free Full Text] - Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood. 1998;92:3240–3249
[Abstract/Free Full Text] - Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol. 2000;36:1514–1519
[Abstract/Free Full Text] - Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost. 1998;79:691–705[Web of Science][Medline]
- Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vase Biol. 1997;17:2309–2315
- Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Cuccurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation. 2000;102:1007–1013
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||